Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Shiaike versus alteplase for acute ST-elevation myocardial infarction
ChiCTR1900023359Phase 4Recruiting
- Sponsor
- Peking University First Hospital
- Start
- May 2019
- Modality
- Recombinant Proteins and Enzymes, Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of staphylokinase and tissue-plasminogen activator in acute ST-segment elevation myocardial infarction (STEMI) (2 arms), sponsored by Peking University First Hospital. Primary endpoint: Total TIMI 3 + TIMI 2 patency rate after treatment. Started May 2019; status: recruiting.
02
Drugs
staphylokinasetissue-plasminogen activator
03
Conditions
acute ST-segment elevation myocardial infarction (STEMI)
Beyond the preview
Go deeper on ChiCTR1900023359.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900023359.